Gongwin Biopharm Holdings Co (ROCO:6617) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co Debt-to-Equity?

Gongwin Biopharm Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$77.14 Mil. Gongwin Biopharm Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$0.03 Mil. Gongwin Biopharm Holdings Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$1,315.49 Mil. Gongwin Biopharm Holdings Co's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gongwin Biopharm Holdings Co's Debt-to-Equity or its related term are showing as below:

ROCO:6617' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 0.13
Current: 0.06

During the past 11 years, the highest Debt-to-Equity Ratio of Gongwin Biopharm Holdings Co was 0.13. The lowest was 0.02. And the median was 0.06.

ROCO:6617's Debt-to-Equity is ranked better than
69.89% of 1066 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6617: 0.06

Gongwin Biopharm Holdings Co Debt-to-Equity Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co Debt-to-Equity Chart

Gongwin Biopharm Holdings Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.03

0.12

0.10

0.06

Gongwin Biopharm Holdings Co Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.10	0.11	0.05	0.06

Competitive Comparison of Gongwin Biopharm Holdings Co's Debt-to-Equity

For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gongwin Biopharm Holdings Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gongwin Biopharm Holdings Co's Debt-to-Equity falls into.

Gongwin Biopharm Holdings Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gongwin Biopharm Holdings Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(77.141	+	0.029)	/	1315.493
	=	0.06

Gongwin Biopharm Holdings Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(77.141	+	0.029)	/	1315.493
	=	0.06

Gongwin Biopharm Holdings Co (ROCO:6617) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gongwin Biopharm Holdings Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gongwin Biopharm Holdings Co (ROCO:6617) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491

Website

http://www.gongwinbiopharm.com

Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co (ROCO:6617) Headlines

No Headlines